Regen BioPharma, Inc. Expands Research Capacity With New Laboratory Facilities

Extensive Product Pipeline Development Necessitated the Need for Expansion

San Diego, CA (Marketwired) - Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the acquisition of new laboratory facilities in La Jolla area of San Diego, California. The laboratory space being leased by Regen is located within the Human BioMolecular Research Institute and provides the Company with access to molecular and cellular biology facilities critical to the Company's cancer stem cell research. Experimental studies in the new laboratory have commenced this week with an initial focus on performing pre-clinical experiments whose objective is the advancement of the Company's cancer stem cell and telomere therapeutic pipeline.

"Regen BioPharma has historically relied on academic collaborators and numerous contract research organizations for advancement of its science. This laboratory space provides us with the capacity to conduct in-house developmental and pre-clinical research with regards to our extensive product pipeline," stated David Koos, Chairman and CEO of Regen. "Given that DifferonC, a gene-silencing based therapeutic for treatment of myelodysplastic syndrome, is our next planned IND, and we have three other downstream pipeline products, it has become important to possess our own laboratory capabilities to most seamlessly and effectively perform critical experiments internally prior to engaging a GLP facility."

About Regen Biopharma Inc.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.